Drug Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Drug Development

Acetohydroxyacid synthase inhibitor active against Mycobacterium tuberculosis

"Acetohydroxyacid synthase (AHAS) is a thiamin diphosphate-(ThDP-) and FAD-dependent enzyme that catalyzes the first common step in the biosynthetic pathway of the branched-amino acids such as leucine, isoleucine, and valine. The genes of AHAS from Mycobacterium tuberculosis were cloned, and overexpressed in E. coli and purified to homogeneity," scientists in South Korea report.

"The purified AHAS from M. tuberculosis is effectively inhibited by pyrazosulfuron ethyl (PSE), an inhibitor of plant AHAS enzyme, with the IC₅₀ ...

• View Other Issues of Drug Week
  
• View Other NewsRx Publications